QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:YMAB

Y-mAbs Therapeutics (YMAB) Stock Price, News & Analysis

$16.26
-0.24 (-1.45%)
(As of 05:22 PM ET)
Today's Range
$15.94
$16.50
50-Day Range
$9.38
$18.69
52-Week Range
$3.13
$20.90
Volume
270,332 shs
Average Volume
413,353 shs
Market Capitalization
$711.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.57

Y-mAbs Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.29 Rating Score
Upside/​Downside
1.4% Upside
$16.57 Price Target
Short Interest
Bearish
6.35% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Y-mAbs Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$28,283 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.43) to ($0.29) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.75 out of 5 stars

Medical Sector

874th out of 938 stocks

Pharmaceutical Preparations Industry

399th out of 433 stocks

YMAB stock logo

About Y-mAbs Therapeutics Stock (NASDAQ:YMAB)

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

YMAB Stock Price History

YMAB Stock News Headlines

Y-mAbs Therapeutics Finance Chief Bo Kruse Resigns
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Y-mAbs Therapeutics CFO Bo Kruse To Retire
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Q4 2023 Y-mAbs Therapeutics Inc Earnings Call
Here's what Wall Street expects from Y-mAbs Therapeutics's earnings
Y-mAbs Therapeutics Inc.
YMAB Mar 2024 20.000 call
YMAB Mar 2024 10.000 call
Y mAbs Therapeutics (YMAB)
Y-mAbs Therapeutics Inc YMAB
See More Headlines
Receive YMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
3/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:YMAB
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.57
High Stock Price Target
$26.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+0.4%
Consensus Rating
Hold
Rating Score (0-4)
2.29
Research Coverage
7 Analysts

Profitability

Net Income
$-21,430,000.00
Pretax Margin
-24.60%

Debt

Sales & Book Value

Annual Sales
$84.82 million
Book Value
$2.32 per share

Miscellaneous

Free Float
34,365,000
Market Cap
$722.37 million
Optionable
Optionable
Beta
0.75
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

YMAB Stock Analysis - Frequently Asked Questions

Should I buy or sell Y-mAbs Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 2 sell ratings, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" YMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in YMAB, but not buy additional shares or sell existing shares.
View YMAB analyst ratings
or view top-rated stocks.

What is Y-mAbs Therapeutics' stock price target for 2024?

7 analysts have issued twelve-month price targets for Y-mAbs Therapeutics' shares. Their YMAB share price targets range from $5.00 to $26.00. On average, they expect the company's share price to reach $16.57 in the next year. This suggests a possible upside of 1.4% from the stock's current price.
View analysts price targets for YMAB
or view top-rated stocks among Wall Street analysts.

How have YMAB shares performed in 2024?

Y-mAbs Therapeutics' stock was trading at $6.82 at the start of the year. Since then, YMAB stock has increased by 139.7% and is now trading at $16.35.
View the best growth stocks for 2024 here
.

When is Y-mAbs Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our YMAB earnings forecast
.

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) posted its earnings results on Thursday, February, 29th. The company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.17. The business earned $23.36 million during the quarter, compared to analysts' expectations of $21.72 million. Y-mAbs Therapeutics had a negative trailing twelve-month return on equity of 20.72% and a negative net margin of 25.26%.

What guidance has Y-mAbs Therapeutics issued on next quarter's earnings?

Y-mAbs Therapeutics updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $95.0 million-$100.0 million, compared to the consensus revenue estimate of $96.3 million.

What other stocks do shareholders of Y-mAbs Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN).

When did Y-mAbs Therapeutics IPO?

Y-mAbs Therapeutics (YMAB) raised $80 million in an IPO on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

Who are Y-mAbs Therapeutics' major shareholders?

Y-mAbs Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.14%), Vanguard Group Inc. (5.13%), Nuveen Asset Management LLC (0.92%), Goldman Sachs Group Inc. (0.91%), Goldman Sachs Group Inc. (0.91%) and Los Angeles Capital Management LLC (0.82%). Insiders that own company stock include Biotech Aps Wg, Bo Kruse, Johan Wedell-Wedellsborg, Thomas Gad and Vignesh Rajah.
View institutional ownership trends
.

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:YMAB) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners